GE HealthCare announced that its FDA‑approved PET myocardial perfusion imaging agent, Flyrcado, will now be deployed at 25 sites within Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the United States. The expansion follows a 21‑patient, two‑week pilot at Cardiovascular Medicine in Davenport, Iowa, where cardiologists performed more than 12 Flyrcado scans per day without disrupting workflow.
CVAUSA’s network performs roughly 85,000 cardiac PET procedures annually, making the new rollout a substantial opportunity for GE HealthCare to capture a larger share of the growing PET myocardial perfusion imaging market. The pilot demonstrated that Flyrcado’s 109‑minute half‑life and superior image quality enable high‑volume practices to adopt the agent without additional logistical burden.
Flyrcado received FDA approval on September 27, 2024, becoming the first new perfusion radiopharmaceutical approved in nearly 30 years. Its longer half‑life compared to other PET tracers improves patient throughput and reduces the need for on‑site radiochemistry facilities, giving GE HealthCare a competitive edge in community cardiology settings.
To support the rollout, GE HealthCare entered a distribution and services agreement with CDL Nuclear Technologies’ CardioNavix division on September 8, 2025. The partnership will provide the necessary supply chain, training, and technical support to enable the 25 CVAUSA sites to begin using Flyrcado in late 2025 and expand throughout 2026.
The expansion aligns with GE HealthCare’s precision‑care strategy, which focuses on delivering personalized, connected diagnostics. The Pharmaceutical Diagnostics division, which now accounts for about 13 % of GE HealthCare’s revenue, grew 20 % YoY in Q3 2025 to $1.02 billion, contributing to the company’s overall 6 % revenue increase to $5.1 billion. Flyrcado’s adoption is expected to reinforce this high‑margin segment and generate incremental revenue as more community practices adopt PET MPI.
Dr. Edmund Coyne, former President of Cardiovascular Medicine, said the pilot “demonstrated that Flyrcado can be seamlessly integrated into a high‑volume cardiac PET practice without disrupting existing workflows.” Tim Attebery, CEO of CVAUSA, added that the network’s 85,000 annual procedures “make the expansion a key part of our mission to deliver the highest quality cardiovascular care.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.